CMS approves ASCs as site of service for a symptomatic uterine fibroid procedure

CMS has approved ASCs as a site of service for transcervical uterine fibroid ablation — a minimally invasive procedure for symptomatic uterine fibroids that can be performed with the Sonata System developed by women’s healthcare company Gynesonics.

Advertisement

CMS has set a device intensive status for the procedure, meaning the total cost of the device is included in the reimbursement rate for ASCs, according to a March 9 press release by Gynesonics.

The reimbursement for ASCs will be $3,632.42 for the transcervical uterine fibroid ablation. For Sonata procedures performed in a hospital outpatient setting, ambulatory payment classification has increased to $6,794.31.

More articles on physicians:
There were 226 ASCs opened in 2019 & 3 more MedPAC 2021 report highlights
Missouri medical group breaks ground on outpatient surgery center
Bundled payments in ASCs: Good business or a race to the bottom?

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in ASC Coding, Billing & Collections

Advertisement

Comments are closed.